1
|
Helissey C, Ghebriou D, Cessot A, Boudin L, Prieux C, Romeo E, Schernberg A, Grellier N, Joly C, Bauduceau O, Thibault C, Mamou E, Raynal G, Serey Eiffel S, Le Floch H, Ricard D, Brureau L. How did we take care of our older cancer patients during the first COVID-19 wave? The French experience. Bull Cancer 2021; 108:589-595. [PMID: 33858619 PMCID: PMC8023196 DOI: 10.1016/j.bulcan.2021.02.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 02/07/2021] [Accepted: 02/10/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND The management of older cancer patients has been highly challenging for clinicians in a health-care system operating at maximum capacity during the COVID-19 pandemic. PATIENTS AND METHODS We analyzed data from 9 different institutions. The primary endpoint was to assess the prevalence of adapted patient care during the pandemic for elderly cancer patients. The secondary endpoint was to assess the incidence of hospitalization and mortality due to COVID-19. All patients were older than 65years of age. RESULTS We analyzed data from 332 outpatients' case files between 9th of March and 30th of April 2020. The median age was 75years (range: 65-101) and 53% were male. Because of the COVID-19 pandemic, more than half of the outpatients received modified patient care, defined as postponement or cancellation of surgery, irradiation scheme adapted, systemic treatment or the use of telemedicine. Among patients with localized cancer, 60% had a change in management strategy due to the pandemic. Changes in management strategy were made for 53% of patients at the metastatic stage. GCSF was used , in 83% of patients, increasing considerably in the context of the pandemic. Sixty-nine percent of physicians used telemedicine. In the final analysis, only one patient was hospitalized for COVID-19 infection. No deaths due to COVID-19 were reported in elderly cancer patients during this time period. CONCLUSION Our study is the first to assess modification of patient care in elderly cancer outpatients during an epidemic. With this unprecedented crisis, our objective is to protect our patients from infection via protective barrier measures and social distancing, but also to guarantee the continuity of cancer care without overexposing this fragile population. Physicians were able to adapt their practice and used new forms of management, like telemedicine.
Collapse
Affiliation(s)
- Carole Helissey
- Military hospital Begin, clinical research unit, 69, avenue de Paris, 94160 Saint-Mandé, France.
| | - Djamel Ghebriou
- AP-HP, Sorbonne université, institut universitaire de cancérologie, Tenon university hospital, department of oncology, 4, rue de la Chine, 75020 Paris, France
| | - Anatole Cessot
- Clinique Hartmann, department of medical oncology, 26, boulevard Victor-Hugo, 92200 Neuilly-sur-Seine, France
| | - Laurys Boudin
- Military hospital Sainte-Anne, department of medical oncology, 2, boulevard Sainte-Anne, BP600, 83000 Toulon, France
| | - Caroline Prieux
- Military Hospital Percy, department of gastroenterology, 2, rue Lieutenant-R.-Batany, 92140 Clamart, France
| | - Emilie Romeo
- Military hospital Sainte-Anne, department of medical oncology, 2, boulevard Sainte-Anne, BP600, 83000 Toulon, France
| | - Anotine Schernberg
- Hôpital Tenon, department of radiation oncology, 4, rue de la Chine, 75020 Paris, France
| | - Noémie Grellier
- Hôpital Henri-Mondor, department of radiation oncology, 1, rue Gustave-Eiffel, 94000 Créteil, France
| | - Charlotte Joly
- Hôpital Henri-Mondor, department of medical oncology, 1, rue Gustave-Eiffel, 94000 Créteil, France
| | - Olivier Bauduceau
- Clinique Hartmann, department of radiation oncology, 26, boulevard Victor-Hugo, 92200 Neuilly-sur-Seine, France
| | - Constance Thibault
- AP-HP, Centre, HEGP, department of medical oncology, 20, rue Leblanc, 75015 Paris, France
| | - Elodie Mamou
- Military hospital Begin, clinical research unit, 69, avenue de Paris, 94160 Saint-Mandé, France
| | - Gauthier Raynal
- Clinique Métivet, department of urology, 48, rue d'Alsace Lorraine, 94100 Saint-Maur-des-Fossés, France
| | - Sophie Serey Eiffel
- Clinique Métivet, department of urology, 48, rue d'Alsace Lorraine, 94100 Saint-Maur-des-Fossés, France
| | - Hervé Le Floch
- Military hospital Percy, department of pulmonology, 2, rue Lieutenant-R.-Batany, 92140 Clamart, France
| | - Damien Ricard
- Military hospital Percy, department of neurology, 2, rue Lieutenant-R.-Batany, 92140 Clamart, France
| | - Laurent Brureau
- CHU de Pointe-à-Pitre, université Antilles, université Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail (Irset), UMR-S 1085, 97110 Pointe-à-Pitre, Guadeloupe
| |
Collapse
|
2
|
Brureau L, Cessot A, Boudin L, Romeo E, Prieux C, Ghebriou D, Schernberg A, Grellier N, Joly C, Bauduceau O, Thibault C, Mamou E, Raynal G, Serey Eiffel S, Le Floch H, Ricard D, Helissey C. Évaluation des pratiques médicales en oncologie dans le contexte de la pandémie de COVID-19 en France. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Helissey C, Cessot A, Boudin L, Romeo E, Prieux C, Ghebriou D, Schernberg A, Grellier N, Joly C, Bauduceau O, Thibault C, Mamou E, Raynal G, Serey Eiffel S, Le Floch H, Ricard D, Brureau L. Evaluation of medical practices in oncology in the context of the COVID-19 pandemic in France: Physicians' point of view: the PRATICOVID study. Cancer Med 2020; 9:8875-8883. [PMID: 33022134 PMCID: PMC7675575 DOI: 10.1002/cam4.3503] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 09/13/2020] [Accepted: 09/15/2020] [Indexed: 01/08/2023] Open
Abstract
The cancer population seems to be more susceptible to COVID‐19 infection and have worse outcomes. We had to adapt our medical practice to protect our patients without compromising their cancer prognosis. The national PRATICOVID study aims to describe the adaptation of cancer patient care for this population. We analyzed data from nine different institutions. The primary endpoint was to assess the prevalence of adapted patient care during the pandemic. The secondary endpoints were to describe the point of view of clinicians and patients during and after the pandemic. We analyzed 435 medical procedures between 9th of March and 30th of April. Because of the COVID‐19 pandemic, 47.6% of the outpatients received modified patient care. Twenty‐four percent of scheduled surgeries were postponed, or were performed without perioperative chemotherapy, 18.4% followed a hypofractioned schedule, and 57% had an adaptive systemic protocol (stopped, oral protocol, and spacing between treatments). Seventy percent of physicians used telemedicine. During this period, 67% of the physicians did not feel distressed taking care of their patients. However, 70% of physicians are worried about the aftermath of the lockdown, as regards future patient care. The PRATICOVID study is the first to assess modification of patient care in cancer outpatients during an epidemic. With this unprecedented crisis, physicians were able to adapt their practice in order to protect their patients against the virus while ensuring continuity of patient care. But physicians are worried about the aftereffects of the lockdown specifically in regard to care pathway issues.
Collapse
Affiliation(s)
- Carole Helissey
- Clinical Research unit, Military Hospital Begin, Saint-Mandé, France
| | - Anatole Cessot
- Department of Medical oncology, Clinique HARTMANN, Neuilly-sur-Seine, France
| | - Laurys Boudin
- Department of Medical oncology, Military Hospital Sainte-Anne, Toulon, France
| | - Emile Romeo
- Department of Medical oncology, Military Hospital Sainte-Anne, Toulon, France
| | - Caroline Prieux
- Department of Gastroenterology, Military Hospital Percy, Clamart, France
| | - Djamel Ghebriou
- Department of Oncology, Tenon University Hospital, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Paris, France
| | | | - Noemie Grellier
- Department of Radiation oncology, Hôpital Henri Mondor, Créteil, France
| | - Charlotte Joly
- Department of Medical Oncology, Hôpital Henri Mondor, Créteil, France
| | - Olivier Bauduceau
- Department of Radiation Oncology, Clinique HARTMANN, Neuilly-sur-Seine, France
| | | | - Elodie Mamou
- Clinical Research unit, Military Hospital Begin, Saint-Mandé, France
| | - Gauthier Raynal
- Department of Urology, Clinque Métivet, Saint-Maur-des Fossés, France
| | | | - Hervé Le Floch
- Department of Pulmonology, Military Hospital Percy, Clamart, France
| | - Damien Ricard
- Department of Neurology, Military Hospital Percy, Clamart, France
| | - Laurent Brureau
- CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR-S 1085, Pointe-à-Pitre, France
| |
Collapse
|
4
|
Helissey C, Cessot A, Boudin L, Romeo E, Prieux C, Ghebriou D, Schernberg A, Grellier N, Joly C, Bauduceau O, Thibault C, Mamou E, Raynal G, Setey Eiffel S, Le Floch H, Ricard D, Brureau L. 1728P Evaluation of medical practices in oncology in a context of COVID-19 pandemic in France: Point of view of physicians, PRATICOVID study. Ann Oncol 2020. [PMCID: PMC7506459 DOI: 10.1016/j.annonc.2020.08.1792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Cohen R, Preta LH, Joste V, Curis E, Huillard O, Jouinot A, Narjoz C, Thomas-Schoemann A, Bellesoeur A, Tiako Meyo M, Quilichini J, Desaulle D, Nicolis I, Cessot A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. Br J Clin Pharmacol 2019; 85:1227-1238. [PMID: 30701582 DOI: 10.1111/bcp.13849] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 10/23/2018] [Accepted: 12/14/2018] [Indexed: 01/30/2023] Open
Abstract
AIMS Cytidine deaminase (CDA) activity in cancer patients' serum has been proposed as a predictive biomarker for efficacy and toxicity of nucleoside analogues. However, discrepant results about its predictive value have been reported due to the high interindividual variability in CDA activity. This study aimed at identifying determinants of this interindividual variability. METHODS From December 2014 to November 2015, 183 patients were prospectively included. Serum CDA activity, biological and clinical characteristics as well as five common single nucleotide polymorphisms (SNPs) in the CDA gene (c.-451C > T, c.-92A > G, c.-33_-31delC, c.79A > C, c.435 T > C) were analysed. Associations between clinical characteristics, pharmacogenetic variants and CDA activity were univariately tested. P < 0.1-candidate variables were analysed through a multivariate analysis. The association between CDA activity and toxicity was assessed for the 56 gemcitabine-treated patients. Intraindividual variability in CDA activity was explored in six pancreatic cancer patients treated with gemcitabine. RESULTS Median CDA activity was 3.97 U mg-1 (range 1.53-15.49 U mg-1 ). A univariate analysis showed that CDA activity was statistically associated with Eastern Cooperative Oncology Group performance status, mild or severe malnutrition, inflammatory syndrome, leucocyte count, neutrophil count, albumin, C-reactive protein and -c.-33_-31delC single nucleotide polymorphism. A multivariate analysis identified that only neutrophil count (P < 0.0001) and severe malnutrition (P = 0.0278) were independently associated with CDA activity. Low CDA activity (<2 U mg-1 ) was not statistically associated with severe gemcitabine-related toxicities (P = 0.16). A decrease in CDA activity was observed during the longitudinal follow-up of six pancreatic cancer patients treated with gemcitabine (P = 0.03). CONCLUSIONS These results suggest that neutrophil count and malnutrition should be considered for the interpretation of pretherapeutic CDA activity.
Collapse
Affiliation(s)
- R Cohen
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - L H Preta
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - V Joste
- Biochemistry Unit, Georges Pompidou European Hospital, Paris Descartes University, AP-HP, Paris, France
| | - E Curis
- Laboratory of biomathematics, plateau iB2, Pharmacy Faculty, University of Paris Descartes, Paris, France
| | - O Huillard
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - A Jouinot
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - C Narjoz
- Biochemistry Unit, Georges Pompidou European Hospital, Paris Descartes University, AP-HP, Paris, France
| | - A Thomas-Schoemann
- UMR8638 CNRS, Paris Descartes University, Pharmacy Faculty, University of Paris Descartes, Paris, France.,Multidisciplinary risk assessment and Drug Monitoring, Cochin Hospital, AP-HP, Paris
| | - A Bellesoeur
- Multidisciplinary risk assessment and Drug Monitoring, Cochin Hospital, AP-HP, Paris
| | - M Tiako Meyo
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - J Quilichini
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - D Desaulle
- Laboratory of biomathematics, EA 4064 Environmental epidemiology and impact of pollution on health, Pharmacy Faculty, University of Paris Descartes, Paris, France
| | - I Nicolis
- Laboratory of biomathematics, EA 4064 Environmental epidemiology and impact of pollution on health, Pharmacy Faculty, University of Paris Descartes, Paris, France
| | - A Cessot
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - M Vidal
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.,UMR8638 CNRS, Paris Descartes University, Pharmacy Faculty, University of Paris Descartes, Paris, France
| | - F Goldwasser
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - J Alexandre
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - B Blanchet
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.,UMR8638 CNRS, Paris Descartes University, Pharmacy Faculty, University of Paris Descartes, Paris, France
| |
Collapse
|
6
|
Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundam Clin Pharmacol 2017; 32:98-107. [PMID: 29055166 DOI: 10.1111/fcp.12327] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2017] [Revised: 09/30/2017] [Accepted: 10/18/2017] [Indexed: 12/18/2022]
Abstract
Therapeutic drug monitoring (TDM) could be helpful in oral targeted therapies. Data are sparse to evaluate its impact on treatment management. This study aimed to determine a threshold value of plasma drug exposure associated with the occurrence of grade 3-4 toxicity, then the potential impact of TDM on clinical decision. Consecutive outpatients treated with sunitinib were prospectively monitored between days 21 and 28 of the first cycle, then monthly until disease progression. At each consultation, the composite AUCƬ,ss (sunitinib + active metabolite SU12662) was assayed. The decisions taken during each consultation were matched with AUCƬ,ss and compared to the decisional algorithm based on TDM. A total of 105 cancer patients and 288 consultations were matched with the closest AUCƬ,ss measurement. The majority (60%) of the patients had metastatic renal clear-cell carcinoma (mRCC). Fifty-five (52%) patients experienced grade 3-4 toxicity. Multivariate analysis identified composite AUCƬ,ss as a parameter independently associated with grade 3-4 toxicity (P < 0.0001). Using the ROC curve, the threshold value of composite AUCƬ,ss predicting grade ≥3 toxicity was 2150 ng/mL/h (CI 95%, 0.6-0.79%; P < 0.0001). At disease progression in patients with mRCC, AUCƬ,ss tended to be lower than the one assayed during the first cycle (1678 vs. 2004 ng/mL/h, respectively, P = 0.072). TDM could have changed the medical decision for sunitinib dosing in 30% of patients at the first cycle of treatment, and in 46% of the patients over the whole treatment course. TDM is routinely feasible and may both contribute to improve toxicity management and to identify sunitinib underexposure at the time of disease progression.
Collapse
Affiliation(s)
- Luc Cabel
- Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Paris Descartes University, CARPEM, Paris, France
| | - Benoit Blanchet
- Department of Pharmacocokinetics and Pharmacochemistry, Groupe de Pharmacologie Clinique Oncologique, Cochin Hospital, Paris, 75014, France
| | - Audrey Thomas-Schoemann
- Department of Pharmacocokinetics and Pharmacochemistry, Groupe de Pharmacologie Clinique Oncologique, Cochin Hospital, Paris, 75014, France.,UMR8638 CNRS, UFR de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
| | - Olivier Huillard
- Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Paris Descartes University, CARPEM, Paris, France
| | - Audrey Bellesoeur
- Department of Pharmacocokinetics and Pharmacochemistry, Groupe de Pharmacologie Clinique Oncologique, Cochin Hospital, Paris, 75014, France
| | - Anatole Cessot
- Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Paris Descartes University, CARPEM, Paris, France
| | - Julie Giroux
- Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Paris Descartes University, CARPEM, Paris, France
| | - Pascaline Boudou-Rouquette
- Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Paris Descartes University, CARPEM, Paris, France
| | - Romain Coriat
- U1016 INSERM, UMR 8104 CNRS, UMR-S1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Department of Gastroenterology, Cochin Hospital, AP-HP, Paris, 75014, France.,Paris Descartes University, CARPEM, Paris, 75006, France
| | - Michel Vidal
- Department of Pharmacocokinetics and Pharmacochemistry, Groupe de Pharmacologie Clinique Oncologique, Cochin Hospital, Paris, 75014, France.,UMR8638 CNRS, UFR de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
| | - Nathaniel E B Saidu
- U1016 INSERM, UMR 8104 CNRS, UMR-S1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Lisa Golmard
- Department of Biological pharmacology, Saint-Louis Hospital, Paris, 75010, France
| | - Jérome Alexandre
- Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Paris Descartes University, CARPEM, Paris, France.,U1016 INSERM, UMR 8104 CNRS, UMR-S1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Francois Goldwasser
- Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Paris Descartes University, CARPEM, Paris, France.,U1016 INSERM, UMR 8104 CNRS, UMR-S1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
7
|
Oudard S, Mejean A, Topart D, Thuret R, Tournigand C, Salomon L, Thiery-Vuillemin A, Guichard G, Le Moulec S, Houlgatte A, Guillot A, Mottet N, Cessot A, Barry-Delongchamps N, Elaidi R, Turajlic S, Swanton C, Escudier B, Patard J, Albiges L. Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, Saidu NEB, Peyromaure M, Zerbib M, Narjoz C, Guibourdenche J, Thomas A, Vidal M, Goldwasser F, Blanchet B, Alexandre J. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer 2016; 72:54-61. [PMID: 28027516 DOI: 10.1016/j.ejca.2016.11.027] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Accepted: 11/09/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND Abiraterone (ABI) is a major oral agent for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients but its systemic exposure is subject to a large inter-individual variability. We aimed to explore the relationship between ABI trough plasma concentration and prostate-specific antigen (PSA) response in mCRPC patients and to identify the critical determinants for its activity. PATIENTS AND METHODS This is a monocentric prospective observational study in mCRPC patients treated with ABI. The plasmatic concentration of ABI at steady state was measured using liquid chromatography with fluorescence detection. The primary objective was to study the relationship between mean ABI plasma exposure (ABI Cmin) and 3-month PSA response. RESULTS From 2012 to 2016, 61 mCRPC patients were eligible for pharmacokinetic/pharmacodynamic assessment. Thirty-eight patients experienced PSA response (62%, [confidence interval {CI} 95% 50-78]). In univariate analysis, ABI Cmin was 1.5-fold higher in responders: 12.0 ng/mL (CI 95% 9.4-15.6) versus 8.0 ng/mL (CI 95% 5.8-11.6; P = 0.0015). In multivariate analysis, only ABI Cmin was independently associated with PSA response (odds ratio = 1.12 [CI 95% 1.01-1.25], P = 0.004). By receiver operating characteristic analysis, the optimal threshold for ABI Cmin was 8.4 ng/mL. Progression-free survival (PFS) was significantly higher in patients with ABI Cmin above 8.4 ng/mL (hazard ratio 0.55, [CI 95% 0.31-0.99], 12.2 [CI 95% 9.2-19.5] versus 7.4 [CI 95% 5.5-14.7] months otherwise, P = 0.044). CONCLUSIONS We showed that ABI trough concentration correlates with PSA response and PFS. Moreover, we could determine a cut-off value of plasmatic concentration for PSA response. Altogether, ABI concentration monitoring appears as a new approach to improve clinical outcome in mCPRC patients.
Collapse
Affiliation(s)
- E Carton
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
| | - G Noe
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - O Huillard
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - L Golmard
- Department of Genetics, Institut Curie, Paris, France
| | - J Giroux
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - A Cessot
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - N E B Saidu
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - M Peyromaure
- Department of Urology, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - M Zerbib
- Department of Urology, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - C Narjoz
- Biochemistry Unit, Georges Pompidou European Hospital, Paris Descartes University, AP-HP, Paris, France
| | - J Guibourdenche
- Hormonology Laboratory, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - A Thomas
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - M Vidal
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - F Goldwasser
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - B Blanchet
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - J Alexandre
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| |
Collapse
|
9
|
Bigot F, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tlemsani C, Chapron J, Huillard O, Cessot A, Vidal M, Alexandre J, Blanchet B, Goldwasser F. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. Invest New Drugs 2016; 35:242-246. [PMID: 27796680 DOI: 10.1007/s10637-016-0400-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 10/20/2016] [Indexed: 12/11/2022]
Abstract
Background Older non-small cell lung cancer (NSCLC) patients under erlotinib are reported to experience more acute toxicity. We hypothesized that modifications in erlotinib pharmacokinetics might explain this observation. Methods A monocentric prospective clinico-pharmacological study included stage IIIb/IV NSCLC consecutive pts. treated with erlotinib. The plasma concentration of erlotinib (Ce) was measured at steady state on day 15. We studied the relationship between age > 75 years, and Ce, using the Mann-Whitney U test and with the occurrence of acute toxicity, using a Fisher's test. Results A total of 53 pts. were analyzed. Median age was 68 years (31-83), 56 % were female. All pts. > 75 years experienced toxicity: all grade acute adverse events were 1.6 fold more frequent (100 % vs 61 %; OR 95 % CI [1.9-INF]; p = 0.003). At day 15, Ce increased with age. Over 75 years old, the mean Ce was 1.5 fold higher: 2091 ng/mL (95 % CI [1476; 2706]) vs 1359 (95 % CI [1029; 1689]; p = 0.024). In pts. over 80 years old, the mean Ce was doubled: 2729 (95 % CI [1961; 3497]) vs 1358 ng/mL (95 % CI [1070; 1646]; p = 0.0019). Reduced lean body mass over 75 years (median 36.6 kg versus 49.1 kg) might account for these differences. Finally, the risk of early erlotinib discontinuation was increased by 11 in older pts. (33 % vs 3 % OR 17.2; 95 % CI [1.7; 892.5] p = .005). Conclusion The risk of overexposure to erlotinib increases with age. Reduced lean body mass may explain erlotinib pharmacokinetics and excessive acute toxicity in the elderly.
Collapse
Affiliation(s)
- Frederic Bigot
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France
| | - Pascaline Boudou-Rouquette
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France.
| | - Jennifer Arrondeau
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France
| | - Audrey Thomas-Schoemann
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France.,UF Pharmacocinétique et pharmacochimie, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Paris, France.,UMR 8638 CNRS, Faculty of Pharmacy of Paris, Université Paris Descartes, SPC, Paris, France
| | - Camille Tlemsani
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France
| | - Jeanne Chapron
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France.,Department of Pneumology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Olivier Huillard
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France
| | - Anatole Cessot
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France
| | - Michel Vidal
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France.,UF Pharmacocinétique et pharmacochimie, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Paris, France.,UMR 8638 CNRS, Faculty of Pharmacy of Paris, Université Paris Descartes, SPC, Paris, France
| | - Jerome Alexandre
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France
| | - Benoit Blanchet
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France.,UF Pharmacocinétique et pharmacochimie, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Francois Goldwasser
- Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France
| |
Collapse
|
10
|
Cohen R, Preta LH, Bessone A, Narjoz C, Nicolis I, Desaulle D, Curis E, Cessot A, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Cohen R, Preta LH, Bessone A, Narjoz C, Nicolis I, Desaulle D, Curis E, Cessot A, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e14096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Romain Cohen
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Laure-Helene Preta
- Laboratory of Toxicology and Pharmacology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | - Aurelia Bessone
- Georges Pompidou European Hospital, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Celine Narjoz
- Georges Pompidou European Hospital, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Ioannis Nicolis
- Laboratoire de Biomathématiques et Informatique, Département de Santé publique et biostatistiques, EA 4064, Faculté de Pharmacie Université Paris Descartes, Paris, France
| | - Dorota Desaulle
- Laboratoire de Biomathématiques et Informatique, Département de Santé publique et biostatistiques, EA 4064, Faculté de Pharmacie Université Paris Descartes, Paris, France
| | - Emmanuel Curis
- Laboratoire de Biomathématiques et Informatique, Département de Santé publique et biostatistiques, EA 4064, Faculté de Pharmacie Université Paris Descartes, Paris, France
| | - Anatole Cessot
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Olivier Huillard
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, AP-HP, CARPEM, Paris, France
| | - Audrey Thomas-Schoemann
- Laboratory of Toxicology and Pharmacology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | - Michel Vidal
- Laboratory of Toxicology and Pharmacology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | - Francois Goldwasser
- Department of Medical Oncology, Cochin Port-Royal Hospital, Paris Descartes University, AP-HP, CARPEM, Immunomodulatory Therapies Multidisciplinary Study group (CERTIM), Paris, France
| | - Jerome Alexandre
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, AP-HP, CARPEM, Immunomodulatory Therapies Multidisciplinary Study group (CERTIM), Paris, France
| | - Benoit Blanchet
- Department of Pharmacokinetics and pharmacochemistry, Cochin Hospital, Paris Descartes University, Immunomodulatory Therapies Multidisciplinary Study group (CERTIM), Paris, France
| |
Collapse
|
12
|
Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. Bull Cancer 2016; 103:259-72. [PMID: 26832420 DOI: 10.1016/j.bulcan.2015.10.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Revised: 10/05/2015] [Accepted: 10/08/2015] [Indexed: 10/22/2022]
Abstract
Angiogenesis inhibition is a major antitumor strategy that has emerged during the last decade. Oral tyrosine kinase inhibitors (TKI) targeting the VEGF receptor, including sunitinib, sorafenib, axitinib, regorafenib, pazopanib, and vandetanib reduce tumor growth and metastasis. These agents are approved for the treatment of metastatic diseases in first or second-line. They display a narrow therapeutic index. However, data in the elderly and/or in patients with multiple illnesses remain scarce. This population is classically excluded from clinical trials. The aim of this review is to provide an overview of existing literature regarding antiangiogenic TKI tolerance in the elderly (>70 years old). We also highlight key points of the pre-therapeutic evaluation and summarize the management of common toxicities.
Collapse
Affiliation(s)
- Marie Bretagne
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France
| | - Pascaline Boudou-Rouquette
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France.
| | - Olivier Huillard
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France
| | - Audrey Thomas-Schoemann
- Hôpitaux universitaires Paris centre, université Paris Descartes, hôpital Broca, hôpital Cochin-Port-Royal, laboratoire de pharmacologie et toxicologie, Paris, France
| | - Anne Chahwakilian
- Hôpitaux universitaires Paris centre, université Paris Descartes, hôpital Broca, hôpital Cochin-Port-Royal, service de gériatrie, Paris, France
| | - Galdric Orvoen
- Hôpitaux universitaires Paris centre, université Paris Descartes, hôpital Broca, hôpital Cochin-Port-Royal, service de gériatrie, Paris, France
| | - Jennifer Arrondeau
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France
| | - Camille Tlemsani
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France
| | - Anatole Cessot
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France
| | - Laure Cabanes
- Hôpitaux universitaires Paris centre, université Paris Descartes, hôpital Broca, hôpital Cochin-Port-Royal, service de cardiologie, Paris, France
| | - Benoit Blanchet
- Hôpitaux universitaires Paris centre, université Paris Descartes, hôpital Broca, hôpital Cochin-Port-Royal, laboratoire de pharmacologie et toxicologie, Paris, France
| | - Romain Coriat
- Hôpitaux universitaires Paris centre, université Paris Descartes, hôpital Broca, hôpital Cochin-Port-Royal, service de gastro-entérologie, Paris, France
| | - Jérôme Alexandre
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France
| | - François Goldwasser
- Hôpitaux universitaires Paris centre, université Paris Descartes, CERIA, Center for Research on Angiogenesis Inhibitors, ARIANE, hôpital Broca, hôpital Cochin-Port-Royal, service d'oncologie médicale, Paris, France
| |
Collapse
|
13
|
Ajgal Z, Chapuis N, Emile G, Cessot A, Tigaud JM, Huillard O, Boudou-Rouquette P, Fontenay M, Goldwasser F, Alexandre J. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer Chemother Pharmacol 2015; 76:1033-9. [DOI: 10.1007/s00280-015-2875-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 09/15/2015] [Indexed: 02/07/2023]
|
14
|
Jouinot A, Vazeille C, Durand J, Neveux N, Cessot A, Boudou-Rouquette P, Giroux J, Gataa I, Bellanger S, Alexandre J, Cynober L, Goldwasser F. 1578 Resting energy expenditure (REE) for risk assessment of anticancer treatments: A prospective study in 277 cancer patients. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30667-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Boudou-Rouquette P, Kreps S, Biau D, Tlemsani C, Rouquette A, Babinet A, Dumaine V, Audard V, Cessot A, Even J, Alexandre J, Chahwakilian A, Housset M, Larousserie F, Goldwasser F, Anract P. 1304 Experience of a monocentric center: Soft-tissue sarcoma in elderly. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30549-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Beinse G, Emile G, Cessot A, Tigaud J, Boudou-rouquette P, Borghese B, Goldwasser F, Pujade-lauraine E, Alexandre J. 2747 A real life experience of bevacizumab in elderly women with advanced ovarian carcinoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31513-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Vazeille C, Jouinot A, Durand JP, Neuveux N, Cessot A, Boudou-Rouquette P, Giroux J, Gataa I, Bellanger S, Alexandre J, De Bandt JP, Goldwasser F. SUN-PP123: The Role of Hypermetabolism in Cancer Cachexia: A Prospective Study in 310 Cancer Patients Prior Chemotherapy Initiation. Clin Nutr 2015. [DOI: 10.1016/s0261-5614(15)30274-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Huillard O, Colombet I, Montheil V, Weiler F, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Cessot A, Giroux J, Alexandre J, Goldwasser F, Vinant P. Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making. Oncologist 2015; 20:e26. [PMID: 26253556 DOI: 10.1634/theoncologist.2015-0131] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
A review article addressing the integration of oncology and palliative care is missing an important indicator: shared decision-making in patient care between oncologists and the palliative care team.
Collapse
Affiliation(s)
- Olivier Huillard
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Isabelle Colombet
- Department of Palliative Medicine, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Vincent Montheil
- Department of Palliative Medicine, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Fabienne Weiler
- Department of Palliative Medicine, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Pascaline Boudou-Rouquette
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Jennifer Arrondeau
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Camille Tlemsani
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Anatole Cessot
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Julie Giroux
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Jerome Alexandre
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - François Goldwasser
- Department of Medical Oncology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| | - Pascale Vinant
- Department of Palliative Medicine, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France
| |
Collapse
|
19
|
Bigot F, Arrondeau J, Boudou-Rouquette P, Chapron J, Thomas-Shoemann A, Cessot A, Huillard O, Tlemsani C, Le Bel A, Vidal M, Alexandre J, Chahwakilian A, Dusser D, Blanchet B, Goldwasser F. Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib? J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.9537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Frederic Bigot
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Jennifer Arrondeau
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | | | - Jeanne Chapron
- Department of Pneumology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Audrey Thomas-Shoemann
- Department of pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Anatole Cessot
- Department of Oncology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | - Olivier Huillard
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Camille Tlemsani
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Audrey Le Bel
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Michel Vidal
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France, Paris, France
| | - Jerome Alexandre
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Anne Chahwakilian
- Department of Gerontology, Paris Descartes University, Broca Hospital, AP-HP, Paris, France, Paris, France
| | - Daniel Dusser
- Department of Pneumology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Benoit Blanchet
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Francois Goldwasser
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| |
Collapse
|
20
|
Arrondeau J, Blanchet B, Thomas-Schoemann A, Huillard O, Boudou-Rouquette P, Giroux J, Cessot A, Tlemsani C, Coriat R, Alexandre J, Vidal M, Goldwasser F. Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.2572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Jennifer Arrondeau
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Benoit Blanchet
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Audrey Thomas-Schoemann
- Department of Oncology, Laboratory of Toxicology and Pharmacology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France., Paris, France
| | - Olivier Huillard
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | | | - Julie Giroux
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Anatole Cessot
- Department of Oncology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | - Camille Tlemsani
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France., Paris, France
| | - Romain Coriat
- Unité D'oncologie Médicale, St. Jacques, Paris, France
| | - Jerome Alexandre
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Michel Vidal
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France, Paris, France
| | - Francois Goldwasser
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| |
Collapse
|
21
|
Jouinot A, Vazeille C, Durand JP, Neveux N, Cessot A, Boudou-Rouquette P, Giroux J, Gataa I, Bellanger S, Alexandre J, Cynober L, Goldwasser F. Risk assessment of anticancer treatments beyond performance status: A prospective study in 277 cancer patients. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.9620] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Anne Jouinot
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Clara Vazeille
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Jean-Philippe Durand
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Nathalie Neveux
- Clinical Biochemistry, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Anatole Cessot
- Department of Oncology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | | | - Julie Giroux
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Ithar Gataa
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Sylvie Bellanger
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Jerome Alexandre
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Luc Cynober
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, Paris, France
| | - Francois Goldwasser
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| |
Collapse
|
22
|
Carton E, Noe G, Huillard O, Giroux J, Cessot A, Peyromaure M, Zerbib M, Narjoz C, Thomas-Schoemann A, Vidal M, Goldwasser F, Blanchet B, Alexandre J. Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.5041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Edith Carton
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Gaelle Noe
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Olivier Huillard
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Julie Giroux
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Anatole Cessot
- Department of Oncology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | - Michael Peyromaure
- Department of Urology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Marc Zerbib
- Department of Urology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Celine Narjoz
- Department of Biochemistry, Paris Descartes University, Georges Pompidou European Hospital, AP-HP, Paris, France
| | - Audrey Thomas-Schoemann
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Michel Vidal
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Francois Goldwasser
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Benoit Blanchet
- Department of Pharmacology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Jérôme Alexandre
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| |
Collapse
|
23
|
Ajgal Z, Chapuis N, Emile G, Cessot A, Tigaud JM, Boudou-Rouquette P, Borghese B, Fontenay M, Goldwasser F, Alexandre J. Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e13569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Zahra Ajgal
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Nicolas Chapuis
- Hematology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - George Emile
- Medical Oncology, Hôpital Beaujon, Clichy, France
| | - Anatole Cessot
- Department of Oncology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, France, Paris, France
| | - jean-Marie Tigaud
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | | | - Bruno Borghese
- Gynecology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Michaela Fontenay
- Hematology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Francois Goldwasser
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | - Jérôme Alexandre
- Department of Oncology, Paris Descartes University, Cochin-Port-Royal Hospital, AP-HP, Paris, France
| |
Collapse
|
24
|
Gougis P, Gazzah A, Bonnet C, Cessot A. Brèves de l’AERIO. ONCOLOGIE 2015. [DOI: 10.1007/s10269-015-2526-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug Metab Toxicol 2015; 11:785-94. [PMID: 25809423 DOI: 10.1517/17425255.2015.1030392] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION UDP-glucuronosyltransferases (UGTs) are a multigenic family of enzymes responsible for the glucuronidation reaction. Many therapeutic classes of drugs used in solid tumors are UGT substrates, including cancer therapies. AREAS COVERED This article describes the tyrosine kinase inhibitors (TKIs) undergoing hepatic glucuronidation; its effect on transport and tissue accumulation and the clinical consequences of this particular metabolism. A PubMed search concerning the pharmacokinetics of the TKIs was performed. All are extensively metabolized by CYP450. Two TKIs, sorafenib and regorafenib, also have a major UGT-mediated metabolism and were therefore studied. EXPERT OPINION The prescription of the same dose of sorafenib and regorafenib for all patients may be inappropriate since at each enzymatic step of this multistep metabolism inter-individual fluctuations exist. Having a non-exclusive CYP-mediated route of metabolism may reduce the risk of variability in drug exposure when CYP3A4 substrates are concomitantly given. Several clinical consequences derive from this pharmacokinetic particularity of sorafenib and regorafenib. Since no clear difference distinguishes TKIs in efficacy in large randomized trials, the differences for the clinical management of their toxicity is a critical aspect.
Collapse
Affiliation(s)
- Camille Tlemsani
- Paris Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA) , Paris , France 33 1 58 41 17 46 ; 33 1 58 41 17 45 ;
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F. Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. Expert Opin Investig Drugs 2015; 24:673-87. [PMID: 25599887 DOI: 10.1517/13543784.2015.1005736] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
INTRODUCTION The platelet-derived growth factor receptor (PDGFR) pathway has important functions in cell growth and, by overexpression or mutation, could also be a driver for tumor development. Moreover, PDGFR is expressed in a tumoral microenvironment and could promote tumorigenesis. With these biological considerations, the PDGFR pathway could be an interesting target for therapeutics. Currently, there are many molecules under development that target the PDGFR pathway in different types of cancer. AREAS COVERED In this review, the authors report the different molecules under development, as well as those approved albeit briefly, which inhibit the PDGFR pathway. Furthermore, the authors summarize their specificities, their toxicities, and their development. EXPERT OPINION Currently, most PDGFR kinase inhibitors are multikinase inhibitors and therefore do not simply target the PDGFR pathway. The development of more specific PDGFR inhibitors could improve drug efficacy. Moreover, selecting tumors harboring mutations or amplifications of PDGFR could improve outcomes associated with the use of these molecules. The authors believe that new technologies, such as kinome arrays or pharmacologic assays, could be of benefit to understanding resistance mechanisms and develop more selective PDGFR inhibitors.
Collapse
Affiliation(s)
- Jennifer Arrondeau
- Paris Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA) , Paris , France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Huillard O, Boudou-Rouquette P, Chahwakilian A, Montheil V, Thomas-Schoemann A, Orvoen G, Cabanes L, Durand JP, Cessot A, Giroux J, Tesniere A, Stephanazzi J, Mosnier-Pudar H, Alexandre J, Goldwasser F. Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.31_suppl.170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
170 Background: Older age is a cause of disparity in cancer treatment decision and treatment guidelines for patients with comorbidities, polypharmacy, denutrition or psycho-social frailty are needed. A pre-therapeutic multidimensional assessment might improve the complex patient management. We developed an experimental program of integrated medicine called ARIANE. We report 18 months activity of this outpatient setting evaluation, its feasibility and impact on treatment decision-making. Methods: Complex patients with predefined cancer treatment strategy entered into the program. A one-day evaluation combined consultations of cardiologist, geriatrician, diabetologist, anesthetist, pharmacist, pain specialist, dietician, psychologist and social worker. Evaluation of performance status, EKG, ejection fraction, ASA score, diabetes, social vulnerability and malnutrition was performed including a geriatric assessment, which focused on items like comorbidity (CIRS-G), dependance (ADL, IADL), fails (Up and Go Test), cognitive impairment (MMSE, Clock Drawing Test) and depression (GDS scale). A pharmacist assessed the risk of drug-drug interactions. Results: Eighty-seven pts, median age 81 years (range 25-94), 76% male, 51% PS 0-1, 77% grade 3 or 4 comorbidity were included. Genito-urinary, lung cancers and sarcoma represented 77% of pts. Eighty-two percent of pts were assessed by at least ≥ 7 participants. Identified factors of vulnerability were polypharmacy (n=65; 75%; >3 drugs), social distress or severe malnutrition (both n=21; 24%), depression (n=17; 19.5%) and cognitive impairment (n=13; 15%). We identified drug interaction in 18 pts (27%). The risk assessment resulted in anticancer treatment changes in 47/87 patients (54%): protocol adaptation (n=19/87; 22%), less aggressive treatment (n=15/87; 17.2%), or more intensive therapy (n=13/87; 15%). Conclusions: A one-day multidisciplinary risk assessment is an answer to the complexity of unfit cancer patients and improves the safety of anticancer treatments.
Collapse
Affiliation(s)
- Olivier Huillard
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | | | - Anne Chahwakilian
- Broca Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Vincent Montheil
- Palliative Medicine, Cochin Teaching Hospital, APHP, Paris, France
| | | | - Galdric Orvoen
- Broca Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Laure Cabanes
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jean-Philippe Durand
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Anatole Cessot
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Julie Giroux
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Antoine Tesniere
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jean Stephanazzi
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Helen Mosnier-Pudar
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jerome Alexandre
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
28
|
Cessot A, Blanchet B, Goldwasser F. Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better. Ann Oncol 2014; 25:2093-2094. [DOI: 10.1093/annonc/mdu261] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Vazeille C, Durand J, Neveux N, Cessot A, Boudou-Rouquette P, Jouinot A, Alexandre J, Cynober L, Goldwasser F. Relationship Between Rest Metabolism and Performance Status in Cancer Patients: a Prospective Study in 161 Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Boudou-Rouquette P, Thomas-Schoemann A, Huillard O, Cessot A, Chahwakilian A, Orvoen G, Giroux J, Durand JP, Vidal M, Blanchet B, Goldwasser F. Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e20523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Olivier Huillard
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Anatole Cessot
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Anne Chahwakilian
- Broca Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Galdric Orvoen
- Broca Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Julie Giroux
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jean-Philippe Durand
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Michel Vidal
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Benoit Blanchet
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
31
|
Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Tesniere A, Cabanes L, Giroux J, Cessot A, Stephanazzi J, Mosnier-Pudar H, Durand JP, Montheil V, Alexandre J, Goldwasser F. Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Olivier Huillard
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | | | - Anne Chahwakilian
- Broca Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Galdric Orvoen
- Broca Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Antoine Tesniere
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Laure Cabanes
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Julie Giroux
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Anatole Cessot
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jean Stephanazzi
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Helen Mosnier-Pudar
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jean-Philippe Durand
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Vincent Montheil
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jerome Alexandre
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
32
|
Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert Opin Drug Saf 2014; 13:663-73. [PMID: 24693873 DOI: 10.1517/14740338.2014.907270] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Sorafenib is a multi-tyrosine kinase inhibitor (TKI). Considerable clinical experience has been accumulated since its first Phase III clinical trial in metastatic renal cancer patients in 2007. The management of its early acute toxicity in fit patients is well known. The management of prolonged treatment becomes the new challenge. AREAS COVERED Using sorafenib as a key word for PubMed search, we review preclinical and clinical data and discuss the pharmacokinetics and pharmacodynamics of sorafenib, its acute and cumulative toxicities and their consequences for patient management. EXPERT OPINION The systematic multi-disciplinary risk assessment of cancer patients prior to TKI initiation reduces the risks of acute and late toxicity, especially drug-drug interactions and arterial risks. Sarcopenia is now identified as a major risk of severe toxicity. The very diverse clinical pictures of cumulative toxicity must be known. The monitoring of sorafenib systemic exposure is helpful especially in elderly patients. Moreover, at disease progression, it allows distinguishing between underexposure to sorafenib and truly acquired resistance to the drug. The optimal use of sorafenib should allow improving the reported results of flat-dose. Finally, most of this knowledge could be used for the development and optimal use of the other TKIs.
Collapse
Affiliation(s)
- Olivier Huillard
- Paris Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA) , Paris , France +33 1 58 41 17 46 ; +33 1 58 41 17 45 ;
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Cessot A, Coriat R, Mir O, Boudou-Rouquette P, Giroux J, Durand JP, Alexandre J, Goldwasser F. Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancer. Nutr Cancer 2013; 65:1254-7. [PMID: 24099412 DOI: 10.1080/01635581.2013.830315] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The increasing number of unfit patients calls for better risk assessment prior to initiating anti-tumor treatment. This is a major concern in the prevention and reduction of treatment-related complications. The aim of our study was to evaluate the nutritional status for the risk assessment of patients qualifying to receive the gemcitabine and oxaliplatin (GEMOX) regimen. This single-center, retrospective study examined baseline clinical and biological characteristics in a cohort of 165 unselected, consecutive cancer patients receiving GEMOX. Malnutrition was defined as either body mass index (BMI) <18.5 kg/m(2), body weight loss >10% over 3 mo, or albuminemia <35 g/L. A total of 165 patients (median age 61 yr, PS 0-1: 71%) were studied. Malnutrition was seen in 43% of PS 0-1 patients, vs. 60% of PS 2 and 66% of PS 3 patients (P > 0.05). Median relative dose-intensity was 0.90 (0.17-1.04). GEMOX dose-intensity correlated negatively with loss of baseline weight (r = -0.24, P < 0.02). In patients who did not complete more than 2 cycles of chemotherapy, median PS (P < 0.01), mean C-reactive protein (CRP; P < 0.01), and mean albuminemia (P < 0.05) were, respectively, significantly higher, higher, and lower. Malnutrition is associated with a high risk of early discontinuance of treatment. Systematic basal evaluation of the nutritional status, including albuminemia and BMI, is recommended.
Collapse
Affiliation(s)
- Anatole Cessot
- a Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique-Hôpitaux de Paris , Paris Descartes University , France
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Giroux J, Alivon M, Briet M, Boudou-Rouquette P, Ropert S, Cessot A, Durand JP, Boutouyrie P, Laurent S, Goldwasser F. Arterial stiffness to predict hypertensive response to antiangiogenic drugs. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e13589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13589 Background: Targeting angiogenesis with anti-VEGF receptors is a new approach for cancer treatment. The most common side effect is arterial hypertension. We hypothesize that pre-existing large artery remodeling with increased arterial stiffness is a determinant of blood pressure (BP) increase under antiangiogenic (AAD) and that AAD may alter mechanical properties of large arteries independently of BP increase. Methods: 49 patients (mean age=57[15] years, mean bSBP=128[22] mmHg and mean DBP=75[11] mmHg; treated for a cancer with an indication to start AAD (Sorafenib, Sunitinib or Bevacizumab) were included in this longitudinal study. Arterial evaluation was assessed at baseline (BL) before the introduction of AAD and every two weeks for 2 months (V1 to V4) with aortic stiffness (PWV) and central BP measurements by aplanation tonometry (SphygmoCor), carotid distensibility with high resolution echotracking system (ArtLab). Results: 43% of the patients developed hypertension between BL and V1. Using linear mixed model analysis with random effects, PWV significantly increased between BL and V1 (BL-V1, adjusted slope 0.89 m/s, F value=6.8, p=0.04) after adjustment to age and mean BP, carotid distensibility decreased significantly during follow-up (BL-V1, adjusted slope= -4.4, p=0.04; BL-V2, adjusted slope= -5.23, p=0.001) after adjustment to age and mean BP. The determinants of BP increase were studied between BL and V1 since anti-hypertensive drugs were introduced after V1. Using multivariate analysis, BL PWV was an independent determinant of the delta brachial SBP (β= -1.36 [-2.61; 0.11], p=0.034) with age (β=0.25 [0.04; 0.47], p=0.02). Conclusions: AAD induce functional alterations of large arteries, increasing arterial stiffness, independently of BP increase. In addition, pre-AAD administration arterial properties influence the hypertensive response to AAD.
Collapse
Affiliation(s)
- Julie Giroux
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Maureen Alivon
- Department of Pharmacology and INSERM U970, Georges Pompidou European Hospital, Paris, France
| | - Marie Briet
- CIC-9201 Clinical Investigation Centre, Georges Pompidou European Hospital, Paris, France
| | | | - Stanislas Ropert
- Department of Oncology, Institut Mutualiste Montsouris, Paris, France
| | - Anatole Cessot
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Jean-Philippe Durand
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Pierre Boutouyrie
- Department of Pharmacology and INSERM U970, Georges Pompidou European Hospital, Paris, France
| | - Stephane Laurent
- Department of Pharmacology and INSERM U970, Georges Pompidou European Hospital, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
35
|
Cessot A, Narjoz C, Thomas-Schoemann A, Boudou-Rouquette P, Golmard JL, Durand JP, Emile G, Tod M, Vidal M, Loriot MA, Blanchet B, Goldwasser F. How to predict sunitinib exposure and toxicity: A pharmacokinetic-pharmacodynamic study. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e15592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15592 Background: Su (su), a tyrosine kinase VEGFR inhibitor, is subject to large inter-individual variability in drug exposure (AUC) and toxicity. We investigated the variability factors influencing AUC as well as the relationship between acute severe toxicity, AUC and genetic polymorphisms in adult cancer patients under su. Methods: The plasma concentrations of su and SU12662 (active metabolite) were assessed on day 7 and 21 of the first cycle. For variability investigation, su, SU 12662 and composite AUC (su+SU12662) were estimated from a population approach, then normalized to 50mg daily dose of su. Genetic polymorphisms for CYP3A4, CYP3A5, CYP1A2, NR1I2, NR1I3, P-gP and BCRP1 were analyzed. Clinical acute toxicity was graded using the NCI 4.0 scale on days 7 and 21. Baseline clinical and biologic characteristics including the lean body mass (LBM), absolute AUC and pharmacogenetic variants were tested univariately for association with toxicities. LBM was simply estimated from gender, height and weight. Candidate variables with p<0.1 were analyzed in a multivariate analysis. Results: Ninety-two pts were evaluable whose 66 for genetic analysis. Sixty-three percent of pts were male, 71% were PS 0-1, 60% had renal carcinoma. A large interindividual variability in normalized composite AUC was observed (CV=40%); LBM and ABCG2polymorphism (421C>A) were identified as major variability factors (p<0.0001 and p=0.014, respectively). Grade³2 hypertension, thrombocytopenia and hand-foot skin reaction were observed in 50, 11 and 10% respectively. Age (OR=1.47 [1.01-2.15], p=0.048) and su AUC (OR=1.16 [1.05-1.28], p=0.005) were independently associated with grade³3 toxicity within the first month, and SU12662 AUC with grade 3 thrombocytopenia (OR=1.27 [1.03-1.57], p=0.028). A formula was built from LBM to define the initial su dose to reach a target composite AUC of 1500ng/mL.h. Conclusions: Monitoring sunitinib and SU12662 exposure may be helpful to prevent severe toxicities. The estimation of LBM, based on gender and anthropometric characteristics, is useful to determine the initial daily dosing of sunitinib.
Collapse
Affiliation(s)
- Anatole Cessot
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Celine Narjoz
- Georges Pompidou European Hospital, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | | | | | | | - Jean-Philippe Durand
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - George Emile
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Michel Tod
- EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon1, Oullins, France
| | - Michel Vidal
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Marie-Anne Loriot
- Georges Pompidou European Hospital, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Benoit Blanchet
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
36
|
Just PA, Cazes A, Audebourg A, Cessot A, Pallier K, Danel C, Vacher-Lavenu MC, Laurent-Puig P, Terris B, Blons H. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. Lung Cancer 2012; 76:309-15. [DOI: 10.1016/j.lungcan.2011.11.004] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Revised: 11/03/2011] [Accepted: 11/05/2011] [Indexed: 11/30/2022]
|
37
|
Mir O, Durand JP, Boudou-Rouquette P, Giroux J, Coriat R, Cessot A, Ropert S, Goldwasser F, Gaillard R. Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. Support Care Cancer 2012; 20:2235-9. [PMID: 22644261 DOI: 10.1007/s00520-012-1503-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2012] [Accepted: 05/20/2012] [Indexed: 12/20/2022]
Abstract
BACKGROUND Previous reports suggested that selective serotonin reuptake inhibitors (SSRI) could decrease the activity of 5-hydroxytryptamine type 3 (5-HT3) antagonists against acute chemotherapy-induced nausea and vomiting (CINV), possibly through serotonin accumulation for 5-HT3 receptors. PATIENTS AND METHODS Chemonaive cancer patients receiving SSRI and antiemetic agents, including the 5-HT3 antagonist ondansetron and the neurokinin 1 (NK1) antagonist aprepitant for highly emetogenic chemotherapy (etoposide-platinum), were matched to control patients for the following variables: age, gender, primary tumor, past history of gestational emesis, chronic intake of benzodiazepines and/or corticosteroids, chronic alcohol intake, and aprepitant use. The primary evaluation criterion was the occurrence of acute vomiting during the first two cycles of treatment. RESULTS Forty-four patients were eligible for this analysis. The proportion of patients, who experienced at least one episode of grade ≥ 1 acute vomiting in patients receiving SSRI, compared to patients who did not, was significantly higher (59.1 vs. 22.7%, respectively, p = 0.03, odds ratio 4.72, 95% confidence interval 1.13-22.88). Grade ≥ 2 acute vomiting was also significantly more frequent in patients receiving SSRI, even after the implementation of aprepitant to antiemetic prophylaxis (41.2 vs. 5.9%, p = 0.04). CONCLUSIONS Our findings reinforce the hypothesis that SSRI decrease the antiemetic activity of the 5-HT3 serotonin antagonist ondansetron, resulting in higher rates of acute vomiting in cancer patients despite adequate antiemetic prophylaxis. Adding the NK1 antagonist aprepitant do not counterbalance the deleterious effect of SSRI, probably due to the synergistic effects of SSRI and NK1 antagonists on serotonin transmission.
Collapse
Affiliation(s)
- Olivier Mir
- Department of Medical Oncology, Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Mir O, Coriat R, Boudou-Rouquette P, Ropert S, Durand JP, Cessot A, Mallet V, Sogni P, Chaussade S, Pol S, Goldwasser F. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol 2012; 29:2793-9. [PMID: 22427209 DOI: 10.1007/s12032-012-0208-x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2012] [Accepted: 03/02/2012] [Indexed: 12/12/2022]
Abstract
Some patients with advanced hepatocellular carcinoma (HCC) progressing under sorafenib remain eligible for further systemic therapy. Little is known on the feasibility of systemic treatment beyond sorafenib in this setting. Consecutive HCC patients pre-treated with sorafenib received gemcitabine 1,000 mg/m² and oxaliplatin 100 mg/m² every 14 days. Exclusion criteria included Child C cirrhosis, PS≥3, creatinine clearance<20 ml/min, albumin<25 g/L and bilirubin>54 μmol/L. Pre-treatment body composition was evaluated by CT scan to detect muscle wasting (sarcopenia). The primary evaluation criterion was safety. Secondary evaluation criteria were response rate, and progression-free (PFS) and overall survival (OS). Eighteen patients (median age: 64 years, range 25-77) received a total of 90 cycles (median per patient: 4, range 1-16). Eight patients (44.4 %) had a PS of 2, 5 (27.8%) had Child-Pugh B cirrhosis and 13 (72.2%) had a CLIP score>3. The most frequent toxicities were thrombocytopenia (grade 2-4: n=7, 38.9%) and peripheral neuropathy (grade 2-3: n=7, 38.9%). The overall response rate was 18.8% (95% CI: 0-37.9), and another 18.8 % of patients had stable disease. The median PFS and OS were 3.2 (95% CI: 2.3-3.9) and 4.7 (95% CI: 3.8-8.1) months, respectively. Overall survival was significantly longer in patients without sarcopenia [10.0 months (95% CI: 7.0-13.8) vs. 3.0 months (95 % CI: 2.5-3.9), p<0.001] and in patients with an ECOG PS<2 [8.1 months (95% CI: 7.0-13.8) vs. 3.8 months (95% CI: 2.5-3.9), p=0.017]. In our experience, gemcitabine-oxaliplatin was feasible and had detectable clinical activity in HCC patients pre-treated with sorafenib. Further studies are needed to confirm these findings.
Collapse
Affiliation(s)
- Olivier Mir
- Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors (CERIA), Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27, rue du faubourg Saint Jacques, 75014, Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012; 23:200-205. [PMID: 21427067 DOI: 10.1093/annonc/mdr045] [Citation(s) in RCA: 141] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Oxaliplatin neurosensory toxicity is dose limiting and may present as acute symptoms and/or cumulative peripheral neuropathy. PATIENTS AND METHODS From October 2005 to May 2008, patients with oxaliplatin-induced acute neurotoxicity were randomized into a double-blind study, to receive either venlafaxine 50 mg 1 h prior oxaliplatin infusion and venlafaxine extended release 37.5 mg b.i.d. from day 2 to day 11 or placebo. Neurotoxicity was evaluated using numeric rating scale (NRS) for pain intensity and experienced relief under treatment, the Neuropathic Pain Symptom Inventory and the oxaliplatin-specific neurotoxicity scale. The primary end point was the percentage of patients with a 100% relief under treatment. RESULTS Forty-eight patients were included (27 males, median age: 67.6 years). Most patients had colorectal cancer (72.9%). Median number of cycles administered at inclusion was 4.5 (mean cumulative oxaliplatin dose: 684.6 mg). Twenty out of 24 patients in arm A (venlafaxine) and 22 out of 24 patients in arm B (placebo) were assessable for neurotoxicity. Based on the NRS, full relief was more frequent in the venlafaxine arm: 31.3% versus 5.3% (P=0.03). Venlafaxine side-effects included grade 1-2 nausea (43.1%) and asthenia (39.2%) without grade 3-4 events. CONCLUSION Venlafaxine has clinical activity against oxaliplatin-induced acute neurosensory toxicity.
Collapse
Affiliation(s)
- J P Durand
- Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris.
| | - G Deplanque
- Department of Medical Oncology, Saint Joseph Hospital, Paris
| | - V Montheil
- Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris
| | - J M Gornet
- Department of Gastro-Enterology, Saint Louis Teaching Hospital, AP-HP, Paris
| | - F Scotte
- Department of Medical Oncology, Georges Pompidou European Hospital, AP-HP, Paris
| | - O Mir
- Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris
| | - A Cessot
- Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris
| | - R Coriat
- Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris
| | - E Raymond
- Department of Medical Oncology, Beaujon Teaching Hospital, AP-HP, Clichy
| | - E Mitry
- Department of Gastro-Enterology, Ambroise Paré Teaching Hospital, AP-HP, Boulogne-Billancourt
| | - P Herait
- Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris
| | - Y Yataghene
- Oncology Unit, Sanofi Aventis France, Paris, France
| | - F Goldwasser
- Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris
| |
Collapse
|
40
|
Durand JP, Mir O, Coriat R, Cessot A, Pourchet S, Goldwasser F. Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients. Support Care Cancer 2011; 20:857-64. [DOI: 10.1007/s00520-011-1163-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2011] [Accepted: 04/04/2011] [Indexed: 02/05/2023]
|
41
|
Pallier K, Cessot A, Cazes A, Just PA, Danel C, Riquet M, Côté JF, Ansieau S, Puisieux A, Laurent-Puig P, Blons HF. Abstract 3418: TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-3418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Metastasis, a recognized multistep biological process, is the main cause of mortality in cancer patients. Although EGFR mutated lung cancers are of better prognosis, a group of patients develop metastasis and died of disease. We previously showed that EGFR mutations were associated with a copy number variation at a locus encompassing the TWIST1 gene on chromosome 7. TWIST1 is a highly conserved developmental gene involved in embryogenesis that turned out to be frequently reactived in cancers promoting both malignant conversion and cancer progression. The aim of this study was to investigate the role of TWIST1 on progression in EGFR mutated lung cancer. Using 6 human lung cell lines with or without EGFR mutations or TWIST1 reactivation, we demonstrated that epithelial-mesenchymal transition (EMT) and the associated mobility were dependent upon TWIST1 expression in cells with EGFR mutation. Indeed, EGF treatment only induced EMT and mobility in cells with TWIST reactivation. EGF treatment induced a translocation of TWIST1 to the nucleus, up-regulated mesenchymal markers and down-regulated epithelial markers at mRNA and protein levels. Moreover, inhibition of either the oncogenic EGF pathway stimulation or TWIST1 expression by small RNA technology reversed the phenomenon suggesting that both EGF pathway activation and TWIST1 reactivation are necessary for EMT in lung cancer with EGFR mutation. In a second step, we analyzed surgical lung cancer specimens from non-smokers with and without EGFR mutations and looked for TWIST1 and epithelial or mesenchymal markers expression. Hierarchical clustering combining TWIST1, epithelial (CDH1, JUP) and mesenchymal (VIM, CDH2) gene mRNA expression in tumors perfectly individualizes the EGFR mutated group as the group with TWIST1 reactivation. Immunohistochemical analysis of lung cancer samples revealed that TWIST1 protein expression was associated with EGFR mutation and low CDH1 expression supporting our in vitro observations. Collectively, our observations support that TWIST1 collaborates with EGF/EGFR mutated signaling pathway in promoting EMT in lung cancers and thereby drives the metastatic dissemination in this group of patients.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3418. doi:10.1158/1538-7445.AM2011-3418
Collapse
|
42
|
Coriat R, Mir O, Cessot A, Brezault C, Ropert S, Durand JP, Cacheux W, Chaussade S, Goldwasser F. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs 2010; 30:376-81. [PMID: 20798975 DOI: 10.1007/s10637-010-9525-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Accepted: 08/16/2010] [Indexed: 12/20/2022]
Abstract
PURPOSE The only drug that improves survival in hepatocellular carcinoma is sorafenib. FOLFOX-4 regimen is safe and widely used in patients with colorectal cancer, yielding interesting results with little toxicity. We conducted a retrospective study to evaluate the safety and the effectiveness of FOLFOX-4 in cirrhotic or liver transplanted patients with hepatocellular carcinoma ineligible for sorafenib. METHODS Thirty seven patients were enrolled in the study. The medical record of either cirrhotic patients or liver transplanted patients with advanced hepatocellular carcinoma receiving FOLFOX-4 regimen between November 1999 and March 2006 were retrospectively analyzed. Patients received oxaliplatin 85 mg/m(2) as a 2-hour infusion on day one, and leucovorin 200 mg/m(2) as a 2-hour infusion followed by bolus 5-fluorouracil 400 mg/m(2) and a 48-hours infusion of 5-fluorouracil 2400 mg/m(2). Treatment was repeated every 2 weeks until disease progression or unacceptable adverse effects occurred. RESULTS Patients had a Child-Pugh class A (n = 16), class B cirrhosis (n = 10) or a liver transplant (n = 11) and received 2 to 37 cycles of chemotherapy (total of 310 cycles). Two (5.4%) cirrhotic patients developed neutropenic sepsis and one (2.7%) toxic death occurred. At first assessment, five patients from Child-Pugh class A (33%) and two from Child-Pugh class B group (20%) achieved a radiological response and/or alpha foeto-protein decrease, and no patient achieved a complete response. CONCLUSIONS In conclusion, with a manageable toxicity profile in cirrhotic Child-Pugh class A-B or liver transplanted patients, the FOLFOX-4 regimen appears to be a feasible treatment option for patients with advanced hepatocellular carcinoma unfit for sorafenib. These data need to be confirmed in a prospective study.
Collapse
Affiliation(s)
- Romain Coriat
- Center for Research on Angiogenesis Inhibitors (CERIA), Université Paris Descartes, AP-HP, Cochin Teaching Hospital, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Locher C, Grivaux M, Cessot A, Blanchon F. 181 Efficacité du Pegfilgrastim dans le cancer bronchopulmonaire (CBP) : résultats d’une étude observationnelle et prospective. Rev Mal Respir 2007. [DOI: 10.1016/s0761-8425(07)72557-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|